Every material Form 8-K Vertex Pharmaceuticals has filed with the SEC since February 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, representing a 12% increase compared to the same period in 2025, driven by cystic fibrosis therapies and newer product growth. The company raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion following strong performance and the closing of the Crinetics Pharmaceuticals acquisition. GAAP net income declined year-over-year to $654 million due to acquisition-related expenses.
Total revenue for the third quarter of 2026 reached $3.44 billion, up 12% year-over-year.
Full-year 2026 revenue guidance was raised to a range of $13.15 billion to $13.25 billion.
GAAP net income was $654 million for the third quarter of 2026, compared to $1.1 billion in the third quarter of 2025.
The acquisition of Crinetics Pharmaceuticals closed on September 1, 2026.
Vertex Pharmaceuticals appointed Daniel Brennan, a former Chief Financial Officer of Boston Scientific, to its board of directors on October 20, 2026, and expanded the board from ten to eleven members. He also joined the Audit and Finance Committee and received a $400,000 restricted stock unit award that vests in October 2027.
Daniel Brennan joined the board on October 20, 2026; board size increased from ten to eleven members.
Brennan retired in June 2025 as Executive Vice President and Chief Financial Officer of Boston Scientific, a role he held from January 2014.
Brennan received a $400,000 restricted stock unit award vesting in October 2027 and joined the Audit and Finance Committee.
The filing reports no related-person transactions requiring disclosure and no arrangement under which Brennan was appointed.
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer on August 27, 2026, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as CFO on that date but will remain Executive Vice President and Chief Operating Officer. The filing discloses Mr. Poole's salary, bonus target and severance terms, which shareholders may review in the 10-Q exhibits later.
Jonathan Poole, 51, becomes EVP and CFO effective January 1, 2027, having been Senior Vice President, Finance at Vertex since March 2020
Charles F. Wagner, Jr. ceases to be CFO on the effective date and remains EVP and Chief Operating Officer
Poole's base salary is $750,000, with a target annual bonus of 90% of base salary
Severance on termination without cause or for good reason is 100% of base salary and target bonus; the change of control agreement covers the period from 90 days before to 12 months after a change of control
Vertex reported second quarter 2026 results on August 3, 2026, with total revenue of $3.33 billion, up 12% from the prior-year quarter, and GAAP net income of $1.1 billion. The company raised its full-year 2026 total revenue guidance, and it also announced a pending acquisition of Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in the third quarter of 2026, which is not reflected in its guidance.
Q2 2026 total revenue was $3.33 billion, up from $2.96 billion in Q2 2025; GAAP net income was $1.10 billion, up from $1.03 billion.
GAAP diluted earnings per share were $4.31, compared with $3.99 a year earlier.
Full-year 2026 total revenue guidance was raised to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion.
Vertex will acquire Crinetics for $85.00 per share in cash, a total equity value of about $10.0 billion, with closing expected in the third quarter of 2026.
Vertex Pharmaceuticals signed a merger agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a equity valuation of $10.0 billion ($8.8 billion net of cash). The deal is unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval and other conditions. Vertex plans to fund it with cash on hand and a $4.5 billion bridge loan, and it is not conditioned on financing.
Merger consideration: $85.00 per Crinetics share in cash, with unvested equity awards accelerated
Expected close in the third quarter of 2026; Vertex says 2026 guidance will be updated at closing
Termination fee payable by Crinetics in specified circumstances: $350,474,425
Financing: $4.5 billion unsecured 364-day bridge loan from Bank of America, BofA Securities and Morgan Stanley Senior Funding
At its May 13, 2026 annual meeting, Vertex shareholders re-elected a 10-member board, ratified Ernst & Young LLP as auditor for 2026, and approved the 2026 Stock and Option Plan, which replaces the 2013 plan. A shareholder proposal on the right to act by written consent also passed, with 126,892,696 votes for and 95,756,148 against.
Proposal 4: 2026 Stock and Option Plan approved with 216,097,268 for and 6,523,460 against
Proposal 5: shareholder proposal on the right to act by written consent approved with 126,892,696 for and 95,756,148 against
Proposal 3: advisory vote on 2025 executive pay approved with 207,918,843 for and 14,522,776 against
Proposal 2: Ernst & Young LLP ratified as independent auditor for the year ending December 31, 2026 with 223,514,070 for
Vertex reported first quarter 2026 total revenue of $2.99 billion, up 8% from the prior-year quarter, and GAAP net income of $1.0 billion versus $646 million a year earlier. The company reiterated its full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, which signals no change to its outlook for shareholders.
Total revenue of $2.99 billion, up 8%; U.S. revenue rose 7% to $1.78 billion and outside the U.S. rose 9% to $1.21 billion
GAAP diluted EPS of $4.02 versus $2.49; non-GAAP diluted EPS of $4.47 versus $4.06
First quarter 2025 GAAP results included a $379.0 million intangible asset impairment charge
Full year 2026 total revenue guidance of $12.95 billion to $13.1 billion reiterated, unchanged
Vertex director Suketu Upadhyay told the board on April 28, 2026 that he will not stand for re-election at the 2026 annual meeting of shareholders. He has been named the forthcoming Chief Financial Officer of Incyte Corporation, and the company said his decision was due to scheduling conflicts and did not involve any disagreement with Vertex. The board intends to reduce its size to ten members after his departure.
Upadhyay informed the board on April 28, 2026 of his decision not to stand for re-election at the 2026 annual meeting.
He will continue to serve on the board until the 2026 annual meeting.
He has been named the forthcoming Chief Financial Officer of Incyte Corporation.
The board intends to reduce its size to ten members; the company said the slate of remaining nominees is otherwise unchanged.
Vertex said it has finished submitting its rolling Biologics License Application to the FDA for povetacicept, seeking accelerated approval for immunoglobulin A nephropathy in adults. Using a priority review voucher, the company expects the FDA review to take six months from the date the FDA accepts the application, rather than the typical ten months.
Rolling BLA for povetacicept in adults with IgAN submission completed
Company used a priority review voucher
Expected FDA review period: six months from acceptance, versus the typical ten months
Vertex reported fourth-quarter 2025 total revenue of $3.19 billion, up 10% from a year earlier, and GAAP net income of $1.19 billion, or $4.65 per diluted share, compared with $913 million, or $3.50 per diluted share, in the fourth quarter of 2024. The company also gave full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, which shareholders can compare with future results.
Q4 2025 GAAP net income was $1.19 billion, or $4.65 per diluted share, versus $913 million, or $3.50 per diluted share, in Q4 2024.
Full year 2025 total revenue was $12.0 billion, up 9%, and GAAP net income was $3.95 billion, compared with a GAAP net loss of $536 million in 2024.
2026 guidance: total revenue of $12.95 billion to $13.1 billion and GAAP R&D, AIPR&D and SG&A expenses of $6.3 billion to $6.45 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vertex Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →